UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Nature communications, 2020-11, Vol.11 (1), p.5824-15, Article 5824

2020

Volltextzugriff (PDF)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Breast cancer research and treatment, 2022-02, Vol.191 (3), p.565-576

2022

Volltextzugriff (PDF)

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

Therapeutic advances in medical oncology, 2018-01, Vol.10, p.1758835918807339

2018

Volltextzugriff (PDF)

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Clinical breast cancer, 2019-02, Vol.19 (1), p.1-9

2019

Volltextzugriff (PDF)

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5270-5277

2009

Volltextzugriff (PDF)

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

The lancet oncology, 2020-10, Vol.21 (10), p.1283-1295

2020

Volltextzugriff (PDF)

Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

Breast Cancer: Basic and Clinical Research, 2015-01, Vol.2015 (2015), p.9-17

2015

Volltextzugriff (PDF)

Apoptosis of multiple myeloma

International journal of hematology, 2004-10, Vol.80 (3), p.224-231

2004

Volltextzugriff (PDF)

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

Breast cancer research and treatment, 2021-09, Vol.189 (2), p.377-386

2021

Volltextzugriff (PDF)

Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN -altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS3-04-GS3-04

2021

Volltextzugriff (PDF)

Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-03-PD14-03

2021

Volltextzugriff (PDF)

Abstract PS5-06: Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS5-06-PS5-06

2021

Volltextzugriff (PDF)

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1037-1037

2018

Volltextzugriff (PDF)

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Breast cancer research and treatment, 2015-10, Vol.153 (3), p.617-624

2015

Volltextzugriff (PDF)

Abstract P4-10-23: Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-10-23

2020

Volltextzugriff (PDF)

IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN -altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS1117-TPS1117

2018

Volltextzugriff (PDF)

Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT049-CT049

2019

Volltextzugriff (PDF)

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production

The Journal of immunology (1950), 2011-03, Vol.186 (6), p.3401-3409

2011

Volltextzugriff (PDF)

Chlorophosphonates: Inexpensive Precursors for Stereodefined Chloro-Substituted Olefins and Unsymmetrical Disubstituted Acetylenes

Journal of organic chemistry, 2000-06, Vol.65 (12), p.3733-3737

2000

Volltextzugriff (PDF)

Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets

Journal of Immunology, 2006-07, Vol.177 (1), p.120-129

2006

Volltextzugriff (PDF)

Abstract P3-11-08: Eribulin/cyclophosphamide (ErC) versus docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in locally advanced HER2-negative breast cancer: A randomized phase II trial of the Sarah Cannon Research Institute

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P3-P3-11-08

2015

Volltextzugriff (PDF)

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.7-14

2014

Volltextzugriff (PDF)

Impact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant chemotherapy (NAC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1048-1048

2015

Volltextzugriff (PDF)

phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Breast cancer research and treatment, 2009-09, Vol.117 (1), p.83-89

2009

Volltextzugriff (PDF)

Abstract 2686: Anti-tumor effects of a folate-immunoglobulin conjugate are enhanced by cytokine treatment in vitro and in vivo

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2686-2686

2011

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Materials Science. Materials In Electronics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(69)

Publikationsform

Sprache

Englisch
(71)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

Apoptosis of multiple myeloma

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)

Abstract PS5-06: Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets)

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Abstract P4-10-23: Expression of PD-L1 is independent of PIK3CA/AKT1/PTEN alterations in triple-negative breast cancer (TNBC) and is not associated with response to ipatasertib (IPAT) plus paclitaxel (PAC)

IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN -altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC)

Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production

Chlorophosphonates: Inexpensive Precursors for Stereodefined Chloro-Substituted Olefins and Unsymmetrical Disubstituted Acetylenes

Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets

Abstract P3-11-08: Eribulin/cyclophosphamide (ErC) versus docetaxel/cyclophosphamide (TC) as neoadjuvant therapy in locally advanced HER2-negative breast cancer: A randomized phase II trial of the Sarah Cannon Research Institute

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer

Impact of sequencing weekly paclitaxel (T) and dose-dense doxorubicin/cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts) receiving neoadjuvant chemotherapy (NAC)

phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab

Abstract 2686: Anti-tumor effects of a folate-immunoglobulin conjugate are enhanced by cytokine treatment in vitro and in vivo

Aktive Filter

Suchergebnisse filtern